Trial Profile
A Phase I/II Study of Glembatumumab Vedotin in Patients With gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Glembatumumab vedotin (Primary)
- Indications Small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors PrECOG
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 22 Jun 2018 Planned End Date changed from 1 Aug 2019 to 1 May 2019.
- 26 Apr 2018 Planned End Date changed from 1 Aug 2020 to 1 Apr 2019.